Skip to main content
Erschienen in: Supportive Care in Cancer 5/2013

01.05.2013 | Original Article

Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer

verfasst von: Benjamin A. Spencer, Beverly J. Insel, Dawn L. Hershman, Mitchell C. Benson, Alfred I. Neugut

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Palliative issues are an important but understudied issue for patients with advanced cancer. Ureteral obstruction is a complication of advanced prostate cancer, usually relieved with placement of retrograde ureteral stent (RUS) or percutaneous nephrostomy (PCN) to palliate symptoms associated with obstructive uropathy and/or renal failure. We investigated predictors of receipt of RUS and PCN and their association with survival for older advanced prostate cancer patients.

Methods

Using the Surveillance, Epidemiology, and End Results–Medicare database, we identified patients aged 65 or older with stage IV (n = 10,848) or recurrent (n = 7,872) prostate cancer. We used multivariable analysis to compare those with ureteral obstruction treated with RUS or PCN to those not treated and to analyze the association between RUS, PCN, and survival.

Results

Sixteen percent (n = 2,958) of the sample developed ureteral obstruction. Compared to no treatment, African Americans were more likely to undergo placement of PCN [odds ratio 1.48, 95 % confidence intervals (CI) 1.03–2.13] than Whites, but equally likely to receive a stent. Subjects of >80 years were less likely to undergo RUS (ages 80–84, 0.41, 95 % CI 0.27–0.63; ages ≥85, 0.30, 95 % CI 0.16–0.54) compared to patients 65–69 years. Subjects who received a PCN were 55 % more likely to die than those who were untreated. There was no difference in survival among those receiving RUS vs untreated. Nine percent of subjects received RUS or PCN within 30 days of dying.

Conclusions

This is the first population-based study to demonstrate a racial disparity in the palliative treatment of advanced prostate cancer. Reasons for disparate care need to be determined so that interventions may be developed.
Literatur
1.
Zurück zum Zitat Kouba E, Wallen EM, Pruthi RS (2008) Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol 180:444–450PubMedCrossRef Kouba E, Wallen EM, Pruthi RS (2008) Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol 180:444–450PubMedCrossRef
2.
Zurück zum Zitat Wong LM, Cleeve LK, Milner AD, Pitman AG (2007) Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol 178:178–183, discussion 83PubMedCrossRef Wong LM, Cleeve LK, Milner AD, Pitman AG (2007) Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol 178:178–183, discussion 83PubMedCrossRef
3.
Zurück zum Zitat Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87:21–24PubMedCrossRef Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87:21–24PubMedCrossRef
4.
Zurück zum Zitat Ku JH, Lee SW, Jeon HG, Kim HH, Oh SJ (2004) Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? Urology 64:895–899PubMedCrossRef Ku JH, Lee SW, Jeon HG, Kim HH, Oh SJ (2004) Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? Urology 64:895–899PubMedCrossRef
5.
Zurück zum Zitat Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128PubMedCrossRef Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128PubMedCrossRef
6.
Zurück zum Zitat Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069, discussion 9PubMedCrossRef Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069, discussion 9PubMedCrossRef
7.
Zurück zum Zitat Shekarriz B, Shekarriz H, Upadhyay J et al (1999) Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 85:998–1003PubMedCrossRef Shekarriz B, Shekarriz H, Upadhyay J et al (1999) Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 85:998–1003PubMedCrossRef
8.
Zurück zum Zitat Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732–748PubMedCrossRef Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732–748PubMedCrossRef
9.
Zurück zum Zitat Du XL, Fang S, Vernon SW et al (2007) Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660–669PubMedCrossRef Du XL, Fang S, Vernon SW et al (2007) Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660–669PubMedCrossRef
10.
Zurück zum Zitat Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258–1267PubMedCrossRef Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258–1267PubMedCrossRef
11.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
12.
Zurück zum Zitat Zeger SL, Liang KY, Albert PS (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics 44:1049–1060PubMedCrossRef Zeger SL, Liang KY, Albert PS (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics 44:1049–1060PubMedCrossRef
13.
Zurück zum Zitat Lee EW, Wei LJ, Amato DA, eds. Cox-type regression analysis for large numbers of small groups of correlated failure time observations; 1992. Lee EW, Wei LJ, Amato DA, eds. Cox-type regression analysis for large numbers of small groups of correlated failure time observations; 1992.
14.
Zurück zum Zitat Sandhu DP, Mayor PE, Sambrook PA, George NJ (1992) Outcome and prognostic factors in patients with advanced prostate cancer and obstructive uropathy. Br J Urol 70:412–416PubMedCrossRef Sandhu DP, Mayor PE, Sambrook PA, George NJ (1992) Outcome and prognostic factors in patients with advanced prostate cancer and obstructive uropathy. Br J Urol 70:412–416PubMedCrossRef
15.
Zurück zum Zitat Oefelein MG (2004) Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 63:1117–1121PubMedCrossRef Oefelein MG (2004) Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 63:1117–1121PubMedCrossRef
16.
Zurück zum Zitat Joshi HB, Adams S, Obadeyi OO, Rao PN (2001) Nephrostomy tube or ‘JJ’ ureteric stent in ureteric obstruction: assessment of patient perspectives using quality-of-life survey and utility analysis. Eur Urol 39:695–701PubMedCrossRef Joshi HB, Adams S, Obadeyi OO, Rao PN (2001) Nephrostomy tube or ‘JJ’ ureteric stent in ureteric obstruction: assessment of patient perspectives using quality-of-life survey and utility analysis. Eur Urol 39:695–701PubMedCrossRef
17.
Zurück zum Zitat Hoffman RM, Gilliland FD, Eley JW et al (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388–395PubMedCrossRef Hoffman RM, Gilliland FD, Eley JW et al (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388–395PubMedCrossRef
18.
Zurück zum Zitat Polednak AP (2003) Black-white differences in survival from late-stage prostate cancer. Ethn Dis 13:220–225PubMed Polednak AP (2003) Black-white differences in survival from late-stage prostate cancer. Ethn Dis 13:220–225PubMed
19.
Zurück zum Zitat Radecka E, Magnusson M, Magnusson A (2006) Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy. Acta Radiol 47:328–331PubMedCrossRef Radecka E, Magnusson M, Magnusson A (2006) Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy. Acta Radiol 47:328–331PubMedCrossRef
Metadaten
Titel
Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer
verfasst von
Benjamin A. Spencer
Beverly J. Insel
Dawn L. Hershman
Mitchell C. Benson
Alfred I. Neugut
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1666-6

Weitere Artikel der Ausgabe 5/2013

Supportive Care in Cancer 5/2013 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.